Outset Medical, Inc. (NASDAQ:OM) Receives Average Recommendation of “Hold” from Analysts

Shares of Outset Medical, Inc. (NASDAQ:OM) have been assigned an average rating of “Hold” from the five ratings firms that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $10.00.

A number of brokerages have recently weighed in on OM. Weiss Ratings upgraded Outset Medical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 7th. TD Cowen reissued a “buy” rating on shares of Outset Medical in a research note on Friday, May 8th.

Outset Medical Stock Down 6.6%

Shares of NASDAQ:OM opened at $4.50 on Thursday. The firm has a 50 day simple moving average of $4.59 and a 200 day simple moving average of $4.26. Outset Medical has a 52 week low of $3.00 and a 52 week high of $16.16. The company has a debt-to-equity ratio of 0.87, a quick ratio of 4.97 and a current ratio of 6.29. The company has a market cap of $84.60 million, a PE ratio of -1.10 and a beta of 1.96.

Outset Medical (NASDAQ:OM) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.08). Outset Medical had a negative return on equity of 58.06% and a negative net margin of 63.06%.The firm had revenue of $31.64 million for the quarter, compared to analysts’ expectations of $28.97 million. As a group, research analysts expect that Outset Medical will post -3.82 earnings per share for the current year.

Insiders Place Their Bets

In other Outset Medical news, CFO Renee Gaeta sold 17,672 shares of the business’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $4.94, for a total value of $87,299.68. Following the completion of the sale, the chief financial officer directly owned 113,753 shares of the company’s stock, valued at $561,939.82. The trade was a 13.45% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 25,337 shares of company stock valued at $115,660. 2.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Outset Medical

A number of large investors have recently bought and sold shares of OM. BML Capital Management LLC acquired a new stake in shares of Outset Medical in the fourth quarter worth about $2,015,000. R Squared Ltd acquired a new position in shares of Outset Medical during the 1st quarter valued at about $65,000. Aristides Capital LLC bought a new position in shares of Outset Medical in the 4th quarter valued at approximately $177,000. Sei Investments Co. raised its stake in shares of Outset Medical by 15.5% in the 1st quarter. Sei Investments Co. now owns 35,366 shares of the company’s stock valued at $136,000 after acquiring an additional 4,738 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its stake in shares of Outset Medical by 4.1% in the 1st quarter. Bank of New York Mellon Corp now owns 62,360 shares of the company’s stock valued at $239,000 after acquiring an additional 2,435 shares in the last quarter.

Outset Medical Company Profile

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.